SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing a sharp stock decline, sparking widespread investor confusion despite recent financial reports indicating better-than-expected performance. The immediate catalyst appears to be market apprehension regarding the debt impact of its substantial acquisition ambitions and a temporary halt in share buybacks. This has divided the community, with many seizing what they call a 'generational' buying opportunity, while others foresee deeper corrections due to perceived growth moderation and sector competition.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to CEO Diane Garrett's recent FoxTV interview, continuous share accumulation by billionaire investor Eric Sprott, and promising high-grade silver drill results, all against a backdrop of surging silver prices. The community is actively discussing massive upside potential and a potential short squeeze, fueled by Sprott's buying and the company's vast untapped resources. Conversely, a vocal skeptical faction highlights the lack of active mining, dilution risks, and perceived overvaluation, warning of an eventual market correction.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending following its announcement of strong Phase 1 clinical trial data for soquelitinib in atopic dermatitis, showcasing high efficacy and a favorable safety profile that excites investors about its blockbuster potential. While the positive results have fueled significant bullish sentiment and speculation around partnerships, a recently announced public offering has simultaneously introduced dilution concerns, leading to mixed community perspectives.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing a sharp downturn as natural gas prices surge due to "mega bullish" cold weather forecasts and an anticipated "short squeeze" in long natural gas positions. The community is actively debating whether to buy KOLD on its significant dip, anticipating a potential reversal in what many perceive as overbought natural gas. Traders are navigating extreme volatility and the inherent decay of these leveraged ETFs, closely watching for further shifts in weather patterns and market sentiment for this "widowmaker" commodity.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid significant business developments, including an expanded multi-year, multi-hundred-million-dollar deal with HD Hyundai and prominent features at Davos showcasing its AI platform's efficiency. Community discussion is polarized between excitement over its AI-driven revenue growth and skepticism concerning its high valuation, alongside recent controversial reports about its work with government agencies like ICE. The company's unique position at the intersection of AI, government, and enterprise continues to fuel intense debate on its ethical implications and future growth trajectory.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following positive FDA guidance requiring no new trials for its ANKTIVA sBLA, with resubmission expected within 30 days, signaling a clear path for label expansion in bladder cancer. The community is highly optimistic about this de-risked pathway, alongside significant international approvals like Saudi Arabia's for NSCLC, fueling strong discussions of a potential short squeeze and the company's broader impact on cancer treatment.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is trending due to significant market volatility driven by conflicting statements from Trump regarding defense contractor operations, initially threatening buybacks but later proposing a massive defense budget increase. This, combined with ongoing global geopolitical tensions and recent strong earnings, has fueled renewed bullish sentiment and sector strength.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and trending discussions, primarily driven by expectations surrounding the potential closure of the TikTok U.S. deal and recent news of a bondholder lawsuit related to AI infrastructure debt. The community is sharply divided, with bulls pointing to the company's substantial cloud backlog and long-term AI growth prospects, while bears voice strong concerns over increasing debt levels and broader AI sector sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relative Strength Alert For Tarsus Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

BMRN or TARS: Which Is the Better Value Stock Right Now?

BMRN vs. TARS: Which Stock Is the Better Value Option?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the company...

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $495,060.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 6,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was sold at an...

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 6,000 Shares

240,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 3rd quarter, according to the company in its most recent 13F...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 7,397 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 7,397 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 7,397 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 7,397 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The shares...

TFG Asset Management GP Ltd Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

TFG Asset Management GP Ltd increased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 40.1% during the 2nd quarter, according to its most recent filing with the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Barclays

Barclays upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Monday...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.35	-$0.30	14.14%	BEAT
Q2 '25	-$0.38	-$0.48	-26.79%	MISSED
Q1 '25	-$0.73	-$0.64	12.31%	BEAT
Q4 '24	-$0.70	-$0.60	14.41%	BEAT

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TARS News

TARSTarsus Pharmaceuticals Inc